Skip to main content

 

Skip to content
  • HOME
  • ABOUT
    VBL
    • COMPANY OVERVIEW
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • ADVISORY BOARDS
  • CANCER
    PROGRAMS
    • OVERVIEW
    • CANCER PLATFORM
    • CANCER PIPELINE
    • PUBLICATIONS
  • INFLAMMATION
    PROGRAMS
    • OVERVIEW
    • INFLAMMATORY PLATFORM
    • INFLAMMATORY PIPELINE
    • PUBLICATIONS
  • VB-600
    PLATFORM
    • OVERVIEW
    • TARGETING MOSPD2 FOR INFLAMMATION
    • TARGETING MOSPD2 FOR CANCER
    • PUBLICATIONS
  • FOR
    PATIENTS
    • OVERVIEW
    • CLINICAL TRIALS
    • GLIOBLASTOMA
    • OVARIAN CANCER
    • THYROID CANCER
    • COMPASSIONATE USE
  • FOR
    PHYSICIANS
    • OVERVIEW
    • CLINICAL TRIALS
    • PHYSICIAN INQUIRIES
    • COMPASSIONATE USE
  • INVESTOR
    RELATIONS
    • IR HOMEPAGE
    • PRESS RELEASES
    • EVENTS AND PRESENTATIONS
    • STOCK INFORMATION
    • ANALYST COVERAGE
    • CORPORATE GOVERNANCE
    • SEC FILINGS
    • INVESTOR FAQ & CONTACTS
  • NEWS
    ROOM

CONTACT

Vascular Biogenics Ltd.

8 HaSatat St.
Modi’in, Israel 7178106

Phone: 972-8-9935000
Fax: 972-8-9935001

For general issues:
businessdev@vblrx.com

For clinical issues:
clinical@vblrx.com

Vascular Biogenics Ltd Confidential and Anonymous Reporting Hotline 1- 855-245-4910

Or via https://www.whistleblowerservices.com/vblt

Post navigation

Follow Us on TwitterFollow Us on LinkedInFollow Us on FacebookFollow Us on YouTube

YOU ARE NOW LEAVING VBLRX.COM.

The site you are about to visit is maintained by a third party who is solely responsible for its content. We encourage you to read the privacy policy of every website you visit.

CANCEL CONTINUE
VASCULAR BIOGENICS
Copyright © 2019 Vascular Biogenics All rights reserved
  • TERMS AND CONDITIONS
  • PRIVACY
  • CONTACT US
Design by: Berliner Design  |  Site by: foothold-systems
Print Friendly, PDF & Email
Israel